Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis associated with autoimmune manifestations on clinical, histological, and laboratory grounds 1.
Distinguishing this entity from other forms of chronic pancreatitis (such as alcohol-induced) is important as steroid treatment is effective both in reversing morphologic changes but also to return pancreatic function to normal 2.
The condition is rare, with an exact incidence unknown but with increasing number cases reported in the literature 3. It is thought to account for 5-11% of chronic pancreatitis cases.
Age of presentation is variable, and there appears to be a male predilection (male to female ratio is 2:1) 3.
Clinical presentation is also variable, including 3,7:
- weight loss
- new onset diabetes
- extrapancreatic manifestations, with lymphocytic infiltration
- elevated IgG and antinuclear antibody levels are seen in >50% of cases
- abdominal pain and acute pancreatitis are unusual
Sometimes serum amylase and lipase are raised as well as raised Alkaline phosphatase.
It is a type of chronic pancreatitis characterised by a heterogenous autoimmune inflammatory process in which prominent lymphocytic infiltration with associated fibrosis of the pancreas causes organ dysfunction.
The cause is unknown though there is a strong basis for an autoimmune process where antibody reaction against carbonic anhydrase and lactoferrin has been postulated 9.
Diagnostic criteria have been established, see article diagnostic criteria for autoimmune pancreatitis for further details 3,8.
Diffusely indurated and firm pancreas, with some patients demonstrating a focal mass.
Collar like periductal infiltrate composed of lymphocytes and plasma cells 4, with the lymphocytes being CD 8+ and CD 4+ T lymphocytes.
Clusters of inflammatory cells also seen in the walls of small veins and nerves as well as medium and large sized vessels.
Interlobular septa are thickened by a proliferation of myofibroblasts and infiltrated by lymphocytes and plasma cells.
Other organs can also be involved with a lymphocytic infiltrate: GB, biliary tree, kidney, lung and salivary glands more commonly.
- IgG4 related sclerosing disease 11-12
- rheumatoid arthritis
- Sjögren syndrome
- inflammatory bowel disease (IBD)
- sclerosing cholangitis
- in Japanese patients: haplotypes DRB1 and DQB1
- diffuse or focal enlargement of the pancreas with loss of definition of pancreatic clefts
- minimal peripancreatic fat stranding, with inflammatory thickening confined to the peripancreatic region not extending into the mesentery, anterior pararenal fascia or lateroconal fascia
- peripancreatic rim of low attenuation "halo" 5
- when focal involvement, typically head and uncinate process and may be iso- or hypo- to pancreatic tissue
- pancreas can appear normal
- pancreatic dilatation may be seen as can biliary dilatation
Contrast enhancement is helpful as autoimmune pancreatitis demonstrates reduced enhancement during the pancreatic phase (~40 seconds) but near normal enhancement at portal venous phase (70 seconds) 6.
Other sites also seen to be involved:
- peripancreatic lymph-nodes >1 cm
- kidney: inflammatory pseudotumours: hypoattenuating lesions
- retroperitoneal fibrosis: with periaortic soft tissue
- pleural effusions
- CBD: strictures
- mediastinal nodes
MRI demonstrates diffuse pancreatic enlargement 5,10.
- T1: decreased signal intensity
- T2: minimal increase in signal intensity
- T1 C+ (Gd): delayed parenchymal enhancement on dynamic imaging.
- shows diffusion restriction with high DWI signal and low ADC signal 13-14.
- the reduction in ADC values can be lower than with pancreatic cancer 13
- DWI signal may be useful as a marker for determining the indication for steroid therapy 15.
MRCP: multiple intrahepatic duct strictures and common bile duct; diffuse narrowing of the main pancreatic duct
Can be normal. Biliary duct abnormalities are common with strictures of the CBD and short intrahepatic duct strictures representing PSC.
Diffuse irregularity and narrowing of the main pancreatic duct (as distinct from pancreatic carcinoma).
Treatment and prognosis
Treatment with steroids usually leads to resolution both of morphological changes and a return to normal pancreatic function, with remission seen in 98% of cases 7. The condition is however also frequently self-limiting, with spontaneous remission rate of up to 74% 7.
Relapse rates are high, seen in 24% of patients treated with steroids. The rate is higher in untreated patients 7.
Autoimmune pancreatitis accounts for 2-6% of patients who undergo pancreatic resection because they are suspected of having pancreatic cancer 5,10.
History and etymology
It was first described in 1995 by Yoshida et al1.
For the diffuse form consider:
In these conditions, the pancreas is heterogeneously enhancing and an irregular pancreatic contour is seen.
For the focal form consider:
- pancreatic ductal adenocarcinoma
- adenocarcinomas tend to have minimal enhancement both on pancreatic (late arterial, ~40 seconds) and hepatic phase imaging, whereas autoimmune pancreatitis demonstrates near normal enhancement during hepatic phase (portal venous, ~70 seconds) 6
- cystic neoplasm (cystic pancreatic mass differential diagnosis)
- solid neoplasm
- nonepithelial pancreatic neoplasms
pancreatitis (mnemonic for the causes)
- gallstone pancreatitis
- interstitial oedematous pancreatitis
- necrotising pancreatitis
- haemorrhagic pancreatitis
- revised Atlanta classification of acute pancreatitis
- chronic pancreatitis
- Ascaris-induced pancreatitis
- tropical pancreatitis
- autoimmune pancreatitis
- emphysematous pancreatitis
- hereditary pancreatitis
- pancreatitis associated with cystic fibrosis
- segmental pancreatitis
- acute pancreatitis
- pancreatic atrophy
- pancreatic lipomatosis
- pancreatic trauma
- 1. Yoshida K, Toki F, Takeuchi T et-al. Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig. Dis. Sci. 1995;40 (7): 1561-8. Pubmed citation
- 2. Sahani DV, Kalva SP, Farrell J et-al. Autoimmune pancreatitis: imaging features. Radiology. 2004;233 (2): 345-52. doi:10.1148/radiol.2332031436 - Pubmed citation
- 3. Finkelberg DL, Sahani D, Deshpande V et-al. Autoimmune pancreatitis. N. Engl. J. Med. 2006;355 (25): 2670-6. doi:10.1056/NEJMra061200 - Pubmed citation
- 4. Notohara K, Burgart LJ, Yadav D et-al. Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases. Am. J. Surg. Pathol. 2003;27 (8): 1119-27. Am. J. Surg. Pathol. (link) - Pubmed citation
- 5. Irie H, Honda H, Baba S et-al. Autoimmune pancreatitis: CT and MR characteristics. AJR Am J Roentgenol. 1998;170 (5): 1323-7. AJR Am J Roentgenol (abstract) - Pubmed citation
- 6. Takahashi N, Fletcher JG, Hough DM et-al. Autoimmune pancreatitis: differentiation from pancreatic carcinoma and normal pancreas on the basis of enhancement characteristics at dual-phase CT. AJR Am J Roentgenol. 2009;193 (2): 479-84. doi:10.2214/AJR.08.1883 - Pubmed citation
- 7. Kamisawa T, Shimosegawa T, Okazaki K et-al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58 (11): 1504-7. doi:10.1136/gut.2008.172908 - Pubmed citation
- 8. Otsuki M, Chung JB, Okazaki K et-al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis. J. Gastroenterol. 2008;43 (6): 403-8. doi:10.1007/s00535-008-2205-6 - Pubmed citation
- 9. Sutton R. Autoimmune pancreatitis--also a Western disease. Gut. 2005;54 (5): 581-3. doi:10.1136/gut.2004.058438 - Free text at pubmed - Pubmed citation
- 10. Takahashi N, Kawashima A, Fletcher JG et-al. Renal involvement in patients with autoimmune pancreatitis: CT and MR imaging findings. Radiology. 2007;242 (3): 791-801. doi:10.1148/radiol.2423060003 - Pubmed citation
- 11. Nishimori I, Otsuki M. Autoimmune pancreatitis and IgG4-associated sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2009;23 (1): 11-23. doi:10.1016/j.bpg.2008.11.017 - Pubmed citation
- 12. Vlachou PA, Khalili K, Jang HJ et-al. IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. Radiographics. 31 (5): 1379-402. doi:10.1148/rg.315105735 - Pubmed citation
- 13. Kamisawa T, Takuma K, Anjiki H et-al. Differentiation of autoimmune pancreatitis from pancreatic cancer by diffusion-weighted MRI. Am. J. Gastroenterol. 2010;105 (8): 1870-5. doi:10.1038/ajg.2010.87 - Pubmed citation
- 14. Taniguchi T, Kobayashi H, Nishikawa K et-al. Diffusion-weighted magnetic resonance imaging in autoimmune pancreatitis. Jpn J Radiol. 2009;27 (3): 138-42. doi:10.1007/s11604-008-0311-2 - Pubmed citation
- 15. Oki H, Hayashida Y, Oki H et-al. DWI findings of autoimmune pancreatitis: comparison between symptomatic and asymptomatic patients. J Magn Reson Imaging. 2015;41 (1): 125-31. doi:10.1002/jmri.24508 - Pubmed citation